Donggu BioPharm Secures Majority Shareholder Status in Areum Medics

Targeting the Global Market with Next-Generation Fillers Using the MIRACLE Method
Synergy with Overseas Businesses in China, Brazil, Mongolia, Laos, and the Philippines

Dongkoo Bio & Pharma announced on the 17th that it has secured a majority shareholder position by signing a new share subscription agreement with Areummedics to expand its beauty and plastic surgery market.

Dongkoo Bio & Pharma plans to actively expand its beauty and plastic surgery business by participating in Areummedics' management and utilizing its sales network.

Areummedics is a company that possesses top-level filler experts in Korea and proprietary platform technology. It applies a differentiated ‘MIRACLE method’ in the filler manufacturing process. The MIRACLE method is a next-generation filler manufacturing technology that overcomes the drawbacks of first-generation fillers, enabling the production of high-elasticity, high-cohesion dual-phasic fillers through its platform technology. It has completed domestic patent registration and maximizes wrinkle improvement effects by precisely controlling the filler’s cross-linking conditions, providing high ease of use during procedures.

Compared to domestic and international competitors, it can produce filler products with superior elasticity and cohesion, and is evaluated as a core technology leading the next-generation filler market.

The filler market is evolving beyond simple cosmetic purposes into innovative therapeutic solutions combined with advanced regenerative medicine technologies. Dongkoo Bio & Pharma is already promoting the development of cell therapies and high-functional cosmeceutical products incorporating immune cell technology through an MOU with Immunis Bio. Through cooperation with Areummedics, it has secured strong competitiveness in the premium filler market. The company has set a strategy to leap forward as a global brand with technological excellence and differentiation in the beauty and plastic surgery market by launching premium fillers applied with advanced regenerative medicine technology beyond the general filler market.

Dongkoo Bio & Pharma will actively target the global beauty and plastic surgery market by maximizing synergies with its ongoing overseas businesses in China, Brazil, Mongolia, Laos, and the Philippines. In Mongolia, it established Dongkoo Bio & Pharma Co., LLC with One All Gate to operate medical service consulting and wholesale consulting businesses. In Laos, it is building a distribution network for emergency pharmaceuticals in drugstores and convenience stores through a local joint venture.

Recently, the global beauty and plastic surgery market has been rapidly growing. According to a report by the global research firm Astute Analytica, the global

beauty and plastic surgery market was valued at $75.6 billion in 2023 and is projected to reach $212.5 billion by 2032.

Leveraging its strength as the number one dermatology prescription company, Dongkoo Bio & Pharma plans to expand its fillers and regenerative medical solutions with differentiated technology into the global market. Dongkoo Bio & Pharma CEO Cho Yong-jun stated, "Through cooperation with Areummedics, we plan to introduce innovative products in the filler and regenerative medicine fields," and added, "We will realize synergies with our ongoing global projects and grow into a brand with global competitiveness."